Oxford Quantum Circuits's £260M: Europe's Largest Quantum Round
OQC closed an oversubscribed £260M Series C in June 2026 — Europe's biggest private quantum funding round — to scale superconducting quantum computing.
European Venture Capital News & Startup Funding
Europe's venture capital market is maturing rapidly, with growing LP appetite for deep tech, defense, fintech, and sovereign AI capabilities. Our European VC coverage tracks fund formation, mega-rounds, and the policy and capital dynamics shaping the continent's startup ecosystem.
European VC Themes
- Deep tech & defense: Robotics, quantum, space, and dual-use technologies
- Sovereign AI: Foundation models, data centers, and national investment programs
- Fund formation: Pan-European funds and sector-specific vehicles
- Hub activity: London, Paris, Berlin, Stockholm, and emerging markets
Browse European venture capital articles for regional funding insight.
Related Articles (59 articles)
-
-
Merantix Capital's €103M AI Fund: Backing Europe's AI-Native Builders
Merantix Capital closed a €103M fund in June 2026 to back early-stage European AI startups across logistics, manufacturing, energy, healthcare, robotics, and physical AI.
-
Factorial's $150M Series D at $2.5B: AI-Native Workforce Operations
Barcelona's Factorial raised $150M Series D at a $2.5B valuation in June 2026, expanding from HR software into AI-powered workforce operations across Europe.
-
Wordsmith's $70M Series B: Edinburgh's Legal AI Hits $100M Total
Edinburgh legal-AI startup Wordsmith raised a $70M Series B in June 2026, backed by Highland Europe and Index Ventures, reaching $100M in total funding.
-
Semble's £30M Series C: Modern Software for Healthcare Providers
UK healthcare-tech company Semble raised a £30M Series C led by Revaia in June 2026, scaling its practice-management platform for clinicians.
-
Ona Therapeutics's $86.6M Series B: Barcelona's ADC Cancer Bet
Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.